Cognitive · Investigational
Galanin
No lawful US pathway
01 · Overview
Galanin is a 29 or 30 amino acid neuropeptide widely expressed in the brain, acting through three G protein-coupled receptor subtypes, GalR1, GalR2, and GalR3, which are considered potential drug targets for neurological disease (PMID 26220265). In rats it exerts a strong modulatory effect on cholinergic transmission in the hippocampus (PMID 8938746).
The peptide has been implicated in cognitive processes, mood regulation, feeding behavior, and neuroprotection, making it a target of interest for neurodegenerative and psychiatric conditions.
02 · Research summary & key findings
In rats, galanin injected into the ventral hippocampus had biphasic, dose-dependent effects on spatial learning (facilitation at a low dose, impairment at a higher dose) and reduced hippocampal acetylcholine release (PMID 8938746). In postmortem Alzheimer disease brains, galanin fibers hyperinnervate cholinergic basal forebrain neurons, and this was associated with preserved expression of neuroprotective genes (PMID 19749437). In a small placebo-controlled crossover study of 10 depressed patients, intravenous galanin produced a short-term reduction in depression ratings (PMID 15219645). No galanin-based therapeutics have advanced to late-stage clinical trials for cognitive disorders.
03 · Regulatory status
Galanin is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
No lawful pathway today
Galanin is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for cognitive support?
Galanin is an investigational compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on cognitive support, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Intravenous
References
- [1]Intravenous administration of the neuropeptide galanin has fast antidepressant efficacy and affects the sleep EEG Psychoneuroendocrinology, 2004. PMID 15219645
- [2]Galanin fiber hyperinnervation preserves neuroprotective gene expression in cholinergic basal forebrain neurons in Alzheimer's disease J Alzheimers Dis, 2009. PMID 19749437
- [3]Galanin receptors as a potential target for neurological disease Expert Opin Ther Targets, 2015. PMID 26220265
- [4]Effects of ventral hippocampal galanin on spatial learning and on in vivo acetylcholine release in the rat Neuroscience, 1996. PMID 8938746
Primary literature
- PubMed: "Galanin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Galanin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Galanin"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Cognitive
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.